Hirotake Furihata

Hirotake Furihata

Auto-generated profile, based on publicly available information

Hirotake Furihata

Ehime University

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 September 2024 in bioRxiv
Verified
Preprint
Open access
PDF file
JSJames B. Shaum
James B. Shaum
MOMiquel Muñoz i Ordoño
Miquel Muñoz i Ordoño
ESErica A. Steen
Erica A. Steen
DWDaniela Vanessa Wenge
Daniela Vanessa Wenge
HCHakyung Cheong
Hakyung Cheong
MEMichael A. Erb
Michael A. Erb
Chemical inducers of proximity (CIPs) stabilize biomolecular interactions, often causing an emergent rewiring of cellular biochemistry. While rational design strategies can expedite the discovery of heterobifunctional CIPs, monovalent, molecular glue-like CIPs have relied predominantly on serendipity. Envisioning a prospective approach to discover molecular glues for a pre-selected target, we hypothesized that pre-existing ligands could be systematically decorated with chemical modifications to empirically discover protein-ligand surfaces that are tuned to cooperatively engage another protein interface. Here, we used sulfur(VI)-fluoride exchange (SuFEx)-based high-throughput chemistry (HTC) to install 3,163 structurally diverse chemical building blocks onto ENL and BRD4 ligands and then screened the crude products for degrader activity. This revealed dHTC1, a potent, selective, and stereochemistry-dependent degrader of ENL. It recruits CRL4 CRBN to ENL through an extended interface of protein-protein and protein-ligand contacts, but only after pre-forming the ENL:dHTC1 complex. We also characterized two structurally distinct BRD4 degraders, including dHTC3, a molecular glue that selectively dimerizes the first bromodomain of BRD4 to SCF FBXO3 , an E3 ligase not previously accessible for chemical rewiring. Altogether, this study introduces HTC as a facile tool to discover new CIPs and actionable cellular effectors of proximity pharmacology.

14 December 2023 in Nature Communications
Verified
Journal Article
Open access
PDF file
KYKohdai Yamada
Kohdai Yamada
RSRyouhei Shioya
Ryouhei Shioya
KNKohei Nishino
Kohei Nishino
HFHirotake Furihata
Hirotake Furihata
AHAtsushi Hijikata
Atsushi Hijikata
TSTatsuya Sawasaki
Tatsuya Sawasaki
Receptor proteins, such as epidermal growth factor receptor (EGFR), interact with other proteins in the extracellular region of the cell membrane to drive intracellular signalling. Therefore, analysis of extracellular protein-protein interactions (exPPIs) is important for understanding the biological function of receptor proteins. Here, we present an approach using a proximity biotinylation enzyme (AirID) fusion fragment of antigen binding (FabID) to analyse the proximity exPPIs of EGFR. AirID was C-terminally fused to the Fab fragment against EGFR (EGFR-FabID), which could then biotinylate the extracellular region of EGFR in several cell lines. Liquid Chromatography-Mass Spectrometry (LC-MS/MS) analysis indicated that many known EGFR interactors were identified as proximity exPPIs, along with many unknown candidate interactors, using EGFR-FabID. Interestingly, these proximity exPPIs were influenced by treatment with EGF ligand and its specific kinase inhibitor, gefitinib. These results indicate that FabID provides accurate proximity exPPI analysis of target receptor proteins on cell membranes with ligand and drug responses.

22 April 2025 in Nature Plants
Verified
Journal Article
Closed access
PDF file
HFHirotake Furihata
Hirotake Furihata
ZZZhangliang Zhu
Zhangliang Zhu
KNKaisei Nishida
Kaisei Nishida
Yasuhito SakurabaYasuhito Sakuraba
Yasuhito Sakuraba
ATAkihiro Tsuji
Akihiro Tsuji
TMTakuya Miyakawa
Takuya Miyakawa

20 January 2024 in bioRxiv
Verified
Preprint
Open access
PDF file
AKAlena Kroupova
Alena Kroupova
VSValentina A. Spiteri
Valentina A. Spiteri
HFHirotake Furihata
Hirotake Furihata
DDDarren Darren
Darren Darren
SRSarath Ramachandran
Sarath Ramachandran
ACAlessio Ciulli
Alessio Ciulli
The ubiquitin E3 ligase cereblon (CRBN) is the target of therapeutic drugs thalidomide and lenalidomide and is recruited by most targeted protein degraders (PROTACs and molecular glues) in clinical development. Biophysical and structural investigation of CRBN has been limited by current constructs that either require co-expression with the adaptor DDB1 or inadequately represent full-length protein, with high-resolution structures of degraders ternary complexes remaining rare. We present the design of CRBN midi , a construct that readily expresses from E. coli with high yields as soluble, stable protein without DDB1. We benchmark CRBN midi for wild-type functionality through a suite of biophysical techniques and solve high-resolution co-crystal structures of its binary and ternary complexes with degraders. We qualify CRBN midi as an enabling tool to accelerate structure-based discovery of the next generation of CRBN based therapeutics. One sentence summary: A novel Cereblon construct (CRBN midi ) allows structural and biophysical enablement of ligand and degrader design

9 February 2023 in Research Square
Verified
Preprint
Open access
PDF file
KYKohdai Yamada
Kohdai Yamada
RSRyouhei Shioya
Ryouhei Shioya
KNKohei Nishino
Kohei Nishino
HFHirotake Furihata
Hirotake Furihata
AHAtsushi Hijikata
Atsushi Hijikata
TSTatsuya Sawasaki
Tatsuya Sawasaki
Receptor proteins, such as epidermal growth factor receptor (EGFR), interact with other proteins in the extracellular region of the cell membrane to drive intracellular signalling. Therefore, analysis of extracellular protein-protein interactions (exPPIs) is important for understanding the biological function of receptor proteins. Here, we demonstrate a new approach using a proximity biotinylation enzyme (AirID) fusion fragment of antigen binding (FabID) to analyse the proximity exPPIs of EGFR. AirID was C-terminally fused to the Fab fragment against EGFR (EGFR-FabID), which could then biotinylate the extracellular region of EGFR in several cell lines. LC-MS/MS analysis indicated that many known EGFR interactors were identified as proximity exPPIs, along with many new candidate interactors, using EGFR-FabID. Interestingly, these proximity exPPIs were influenced by treatment with EGF ligand and its specific kinase inhibitor, gefitinib. These results indicate that FabID provides accurate proximity exPPI analysis of target receptor proteins on cell membranes with ligand and drug responses.

18 November 2022 in Research Square
Verified
Preprint
Open access
PDF file
TSTatsuya Sawasaki
Tatsuya Sawasaki
SYSatoshi Yamanaka
Satoshi Yamanaka
HFHirotake Furihata
Hirotake Furihata
YIYuuki Imai
Yuuki Imai
YYYuta Yanagihara
Yuta Yanagihara
MTMasaru Tanokura
Masaru Tanokura
Lenalidomide, an immunomodulatory drug (IMiD), is commonly used as first-line therapy in many haematological cancer diseases, such as multiple myeloma (MM) and 5q myelodysplastic syndromes (5q MDS), and it functions as a molecular glue for the protein degradation of neosubstrates by CRL4CRBN 1–4. Proteolysis-targeting chimeras (PROTACs) using IMiDs with a target protein binder also induce the degradation of target proteins5,6. The targeted protein degradation (TPD) of neosubstrates is crucial for IMiD therapy2–4,7. However, current IMiDs and IMiD-based PROTACs also unexpectedly break down neosubstrates involved in embryonic development and disease progression2–4,8–10. Here, we showed that 6-position modifications of lenalidomide are essential for controlling neosubstrate selectivity; 6-fluoro lenalidomide induced the selective degradation of IKZF1, IZKF3, and CK1α, which are involved in anti-haematological cancer activity2–4, and showed stronger antiproliferative effects on MM and 5q MDS cell lines than lenalidomide. PROTACs using the new lenalidomide derivatives for BET proteins induced the selective degradation of BET proteins with the same neosubstrate selectivity. PROTACs also exerted antiproliferative effects in all cell lines examined, including MM and neuroblastoma cell lines. Thus, 6-position-modified lenalidomide is a key strategy for selective TPD using thalidomide derivatives and PROTACs.